You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
A selective and potent GluK1 (formerly GluR5) kainate receptor agonist (Ki = 4.3 nM), inactive at GluK6 (formerly GluR6) (Ki > 1 mM) and only weakly active at AMPA receptors (GluA1-4) and the kainate receptors GluK5 (formerly KA-2) and GluK3 (formerly GluR7) (Ki values of 6 - 14 μM).
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||2.28||10 with gentle warming|
|1eq. NaOH||4.57||20 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 228.25. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||21.91 mL||109.53 mL||219.06 mL|
|1 mM||4.38 mL||21.91 mL||43.81 mL|
|2 mM||2.19 mL||10.95 mL||21.91 mL|
|10 mM||0.44 mL||2.19 mL||4.38 mL|
References are publications that support the biological activity of the product.
Clarke et al (1997) A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 389 599 PMID: 9335499
Matzen et al (1997) AMPA receptor agonists: synthesis, protolytic properties, and pharmacology of 3-isothiazole bioisasteres of glutamic acid. J.Med.Chem. 40 520 PMID: 9046343
Moldrich et al (1999) Excitotoxic injury profiles of low-affinity kainate receptor agonists in neuronal cultures. Eur.J.Pharmacol. 378 R1 PMID: 10478637
If you know of a relevant reference for ATPA, please let us know.
View Related Products by Product Action
Keywords: ATPA, ATPA supplier, Selective, potent, GluR5, agonists, Glutamate, Kainate, Receptors, iGlur, Ionotropic, GluK1, 1107, Tocris Bioscience
7 Citations for ATPA
Citations are publications that use Tocris products. Selected citations for ATPA include:
Song et al (2015) MinCyc does not affect long-term potentiation in the anterior cingulate cortex of normal adult mice. Front Pediatr 11 25 PMID: 25933605
Langner et al (2017) Kynurenic Acid Induces Impairment of Oligodendrocyte Viability: On the Role of Glutamatergic Mechanisms. Neurochem Res 42 838 PMID: 27444613
Talpalar and Kiehn (2010) Glutamatergic mechanisms for speed control and network operation in the rodent locomotor CpG. Front Neural Circuits 4 PMID: 20844601
Liu et al (2004) Astrocyte-mediated activation of neuronal kainate receptors. Mol Pain 101 3172 PMID: 14766987
Dargan et al (2009) ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology 56 121 PMID: 18789344
Randall et al (2011) Fast oscillatory activity induced by kainate receptor activation in the rat basolateral amygdala in vitro. Eur J Neurosci 33 914 PMID: 21255131
Xu et al (2006) Presynaptic regulation of the inhibitory transmission by GluR5-containing kainate receptors in spinal substantia gelatinosa. Mol Pain 2 29 PMID: 16948848
Do you know of a great paper that uses ATPA from Tocris? Please let us know.
Reviews for ATPA
There are currently no reviews for this product. Be the first to review ATPA and earn rewards!
Have you used ATPA?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.